A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.

TPS4150Background: mPAC has a poor prognosis, with a 5-year survival rate of 2.3%. CDK4/6 is often deregulated in mPAC due to loss of CDKN2A via homozygous deletion or epigenetic silencing, resulti...